- Mechanism targets both integrated virus and cccDNA; expected to begin clinical testing by end of 2024 DURHAM, N.C. & SEATTLE--(BUSINESS WIRE)--Pioneering epigenome editing company Tune Therapeutics ...
Pioneering epigenome editing company Tune Therapeutics has announced it is working on a new and potentially curative approach to treating chronic HBV infection. Image Credit: Tune Therapeutics The ...
DURHAM, N.C. & SEATTLE--(BUSINESS WIRE)--Pioneering epigenome editing company Tune Therapeutics has announced it is working on a new and potentially curative approach to treating chronic HBV infection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback